Estimation Of Interleukin 6 Levels And Its Correlation With Severity Of Chronic Heart Failure
Abstract
Background: Chronic heart failure is associated with persistent systemic inflammation, which contributes to ventricular dysfunction and disease progression. Interleukin-6 (IL-6) is a pro-inflammatory cytokine that may reflect the severity of myocardial impairment. Evaluating its relationship with clinical and echocardiographic parameters may help clarify its potential role as a biomarker in chronic heart failure. Aim and Objectives: To estimate serum IL-6 levels in patients with chronic heart failure and determine their correlation with disease severity, assessed using New York Heart Association (NYHA) functional class and left ventricular ejection fraction (LVEF). Results: The study included 45 patients with chronic heart failure. NYHA Classes II, III and IV comprised 21 (46.67%), 17 (37.78%) and 7 (15.56%) patients, respectively. The overall mean LVEF was 41 ± 9%. Mean LVEF declined significantly from 49 ± 7% in NYHA Class II to 35 ± 4% in Class III and 33 ± 4% in Class IV (p=0.001). NYHA class demonstrated a strong negative correlation with LVEF (r=−0.669; p=0.001). The overall mean serum IL-6 level was 16.68 ± 4.49. Mean IL-6 levels were 15.83 ± 4.04, 17.50 ± 4.62 and 17.27 ± 5.63 in NYHA Classes II, III and IV, respectively, without a statistically significant difference (p=0.254). IL-6 showed a weak, non-significant positive correlation with NYHA class (r=0.153; p=0.316). However, IL-6 demonstrated a statistically significant moderate negative correlation with LVEF (r=−0.480; p=0.001). Conclusion: Serum IL-6 was significantly associated with reduced LVEF but not with NYHA functional class. These findings suggest that IL-6 may reflect objective echocardiographic impairment more closely than symptom-based functional severity. Serum IL-6 may therefore serve as a supplementary marker of myocardial dysfunction in chronic heart failure...